Showing results (71-80 of 245) with videos related to
Sort By:
Pageof 25
Investigational New Drugs|January 20, 2015
The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrationsTrevor J Mathias, Karthika Natarajan, Suneet Shukla, et al.Translational Oncology|November 22, 2021
PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancersAnna J Dellomo, Rachel Abbotts, Christian L Eberly, et al.Leukemia Research|April 8, 2004
Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemiaAttaya Suvannasankha, Hans Minderman, Kieran L O'Loughlin, et al.Haematologica|November 13, 2012
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adultsDan P Zandberg, Ting-Ying Huang, Xuehua Ke, et al.Blood|January 5, 2002
Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survivalMustafa Benekli, Zheng Xia, Kathleen A Donohue, et al.International Journal of Hematology|March 6, 2013
Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practiceMartin S Tallman, George B McDonald, Laurie D DeLeve, et al.Oncotarget|July 5, 2016
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stressKshama A Doshi, Rossana Trotta, Karthika Natarajan, et al.Journal of Comparative Effectiveness Research|August 15, 2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M Zeidan, Franklin Hendrick, Erika Friedmann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2Weiguo Liu, Maria R Baer, Mary Jo Bowman, et al.Oncology Reports|February 1, 2014
Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cellsYue-Li Sun, Priyank Kumar, Kamlesh Sodani, et al.Pageof 25